Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > this is what a good bio therapeutic
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Comment by davgroon Apr 27, 2022 3:04pm
97 Views
Post# 34636538

RE:this is what a good bio therapeutic

RE:this is what a good bio therapeutic
Duster340 wrote: company should look like (my best kept secret still time to get in guys) LYRA

Yo Dust Pan, why are you posting this on the ATE board.  Are you implying that ATE is not a "good bio therapeutic" company.  And if so, then why did you buy 7000+ shares of ATE just last week at $0.76 and $0.77.

I really think your meds aren't working and you need a "good bio therapeutic" medication.  Are you not tired of embarrasssing yourself with these irrelevant posts and childish YouTube memes ??

Most members don't see your posts as they put you on ignore a long time ago.  I won't do that as I find your antics entertaining.  It's kind of like watching Rudy Giuliani's life implode in the public eye.  He is  oblivious to how stupid he looks, just like you.  Maybe you should go on the Masked Singer.  LMAO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities